Controlled specific immunotherapy of the nasal atopy.
61 extrinsic nasal atopic patients (26 Grass-positive, 35 D.pt.-positive) underwent a longitudinal study of some clinical-diagnostic parameters in order to establish their usefulness for a specific controlled therapy. The symptoms diary drawn up by the patient himself together with the research of the threshold and nasal responsiveness by the RRM provocation test and the evaluation on the same patient of the endo-point of the blocking antibodies result, at present time, the most suitable means to carry out in a satisfactory way a controlled specific therapy.
D000906:Antibodies; D001667:Binding, Competitive; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007167:Immunotherapy; D009297:Nasal Mucosa / Q000378:metabolism; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*
D000906:Antibodies; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007073:Immunoglobulin E